Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Prevention or Retention?

被引:2
作者
Schneider, Tim [1 ]
机构
[1] PUR R Praxisklin Urol Rhein Ruhr, D-45468 Mulheim, Germany
关键词
Acute urinary retention; Benign prostatic hyperplasia; Lower urinary tract; Symptoms; Prevention; Surgery; Treatment; Trial without catheter;
D O I
10.1016/j.eursup.2008.08.005
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Acute urinary retention (AUR) is a severe complication of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). The prevention and management of AUR is subject to debate and varies considerably among countries. Objective: To review the current and future prevention and management of AUR secondary to LUTS/BPH. Evidence acquisition: This paper summarises the content of an update lecture that was part of a symposium on the management of LUTS/BPH held at the annual meeting of the European Association of Urology (EAU) in 2008. During the symposium, the results of a Web-based survey evaluating urologists' opinions on the management of LUTS/BPH were also presented and discussed. Evidence synthesis: Prevention of AUR secondary to LUTS/BPH implies delaying the progression of this condition in patients at risk. Risk factors for AUR include the following: an advanced age, moderate-to-severe lower urinary tract symptoms (LUTS), an enlarged prostate, a low peak urinary flow rate, an elevated postvoid residual, and an elevated prostate-specific antigen (PSA) level. Chronic inflammation of the prostate might also be a predictor of AUR. First-line treatment of AUR usually involves decompression of the bladder by catheterisation, which can be followed by a trial without catheter (TWOC) or immediate surgery. Elective surgery after TWOC is preferred to immediate surgery because it is associated with a lower morbidity and mortality risk. Treatment with an alpha(1)-adrenoceptor (alpha(1)-AR) antagonist can increase the success rate of a TWOC. Conclusions: Prevention and management of AUR secondary to LUTS/BPH should be based on the presence of risk factors. In most cases, elective surgery after TWOC is preferred to immediate surgery. Treatment with alpha(1)-AR antagonists is usually indicated when performing a TWOC. (c) 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:696 / 701
页数:6
相关论文
共 15 条
[1]  
BOWDEN E, 2001, BJU INT, V88, P77
[2]  
CHAN PSF, 1996, BR J UROL, V77, P7
[3]   Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo [J].
Crawford, ED ;
Wilson, SS ;
McConnell, JD ;
Slawin, KM ;
Lieber, MC ;
Smith, JA ;
Meehan, AG ;
Bautista, OM ;
Noble, WR ;
Kusek, JW ;
Nyberg, LM ;
Roehrborn, CG .
JOURNAL OF UROLOGY, 2006, 175 (04) :1422-1426
[4]   Management of acute urinary retention [J].
Fitzpatrick, JM ;
Kirby, RS .
BJU INTERNATIONAL, 2006, 97 :16-20
[5]   Natural history of prostatism: Risk factors for acute urinary retention [J].
Jacobsen, SJ ;
Jacobson, DJ ;
Girman, CJ ;
Roberts, RO ;
Rhodes, T ;
Guess, HA ;
Lieber, MM .
JOURNAL OF UROLOGY, 1997, 158 (02) :481-487
[6]   Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia [J].
Lucas, MG ;
Stephenson, TP ;
Nargund, V .
BJU INTERNATIONAL, 2005, 95 (03) :354-357
[7]   Alfuzosin 10 mg once daily in the management of acute urinary retention: Results of a double-blind placebo-controlled study [J].
McNeill, SA ;
Hargreave, TB ;
Roehrborn, CG .
UROLOGY, 2005, 65 (01) :83-89
[8]   Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention [J].
McNeill, SA ;
Hargreave, TB .
JOURNAL OF UROLOGY, 2004, 171 (06) :2316-2320
[9]  
McVary KT, 2006, AM J MANAG CARE, V12, pS122
[10]   A 6-month large-scale study into the safety of tamsulosin [J].
Michel, MC ;
Bressel, HU ;
Goepel, M ;
Rübben, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (06) :609-614